A once-daily pill helped almost double survival time for patients with an aggressive and advanced form of pancreatic cancer when compared to chemotherapy, a trial has found.
The drug also caused fewer side-effects, with experts hailing daraxonrasib as “landscape-changing” for people with the disease.
